The Management of GORD in clinical practice (MOGIC) study
Research type
Research Study
Full title
MOGIC Study - The Management of Gastro-oesophageal reflux disease (GORD) in clinical practice: an international multi centre observational study
IRAS ID
200363
Contact name
Adam Farmer
Contact email
Sponsor organisation
Reckitt Benckiser
Duration of Study in the UK
0 years, 6 months, 1 days
Research summary
Gastro-oesophageal reflux disease (GORD) affects between 10-20% of the UK adult population and is characterized by heartburn, regurgitation and chest discomfort. GORD is the involuntary movement of gastric contents to the oesophagus. GORD is a normal physiological process that occurs several times a day without symptoms or damage of the oesophageal mucosa in most otherwise healthy individuals. GORD is a condition in which reflux of gastric contents into the oesophagus produces frequent or severe symptoms that negatively affect an individual’s quality of life or result in damage to the oesophagus, pharynx or the respiratory tract. The standard of care is currently acid-suppressing medications such as proton pump inhibitors (PPI). Nevertheless, there are a group of patients who become refractory to PPI. The aim of this multinational multi-centre observational study is to assess symptom prevalence, severity, and current associated treatment practices, in a real world population of GORD patients currently on acid-suppressing medication, using validated questionnaires.
REC name
North of Scotland Research Ethics Committee 1
REC reference
16/NS/0026
Date of REC Opinion
11 Mar 2016
REC opinion
Favourable Opinion